Abstract
Liposomes, as non-covalently bound carriers, biocompatible and biodegradable, have raised considerable interest as a drug delivery system in cancer chemotherapy (Gregoriadis, 1988). Most applications of liposomes in cancer chemotherapy are directed at altering tissue distribution and various pharmacokinetic parameters of the drug in question in such a way that toxicity can be reduced and/or efficacy increased (Mayhew and Papahadjopoulos, 1983). Reduced toxicity may be gained through site circumvention of drug sensitive tissues and by slow release of the cytotoxic agent from the carrier, avoiding peak plasma concentrations after bolus injection of free drug. Liposome- mediated decrease in toxicity could enable escalation of dose, which will result in increased tumor exposure to the drug.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Allen, T.M., Hansen, C.B., and Guo, L.S.S., 1993, Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim. Biophys. Acta, 1150:9.
Cabanes, A., Tzemach, D., Goren, D., Horowitz, A.T., and Gabizon A., 1998, Comparative study of the anti-tumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model, Clin. Cancer Res. 4:499.
Forssen, E.A., and Tokes, Z.A., 1981, Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity, Proc Natl Acad Sci 78:1873.
Forssen, E.A., and Tokes, Z.A., 1983, Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes, Cancer Res. 43:546.
Gabizon, A., 1992, Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes, Cancer Res. 52:891.
Gabizon, A., 1995, Liposome circulation time and tumor targeting:implications for cancer chemotherapy, Adv. Drug DelivRev. 16:285.
Gabizon, A., Meshorer, A., and Barenholz, Y., 1986b, Comparative long term study of the toxicities of free and liposomes associated doxorubicin in mice after intravenous administration, J.Natl. Cancer Inst. 77:459.
Gabizon, A., Goren, D., and Barenholz, Y., 1988a, Investigation on the antitumor efficacy of liposome-associated doxorubicin in murine tumor models, Isr. J. Med Sci. 24:517.
Gabizon, A., Barenholz, Y., and Bialer, M, 1993a, Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs, Pharm. Res. 10:703.
Gabizon, A., Goren, D., Ramu, A., and Barenholz, Y., 1986a, Design, characterization and anti-tumor acticity of adriamycin containing phospholipid vesicles, In: Targeting of Drugs with Synthetic Systems, G. Gregoriadis, J. Senior, G. Poste eds., Plenum, London.
Gabizon, A., Goren, D., Fuks, Z., Meshorer, A., and Barenholz, Y., 1985, Superior therapeutic activity of liposome associated adriamycin in a murine metastatic tumor model, Br.J. Cancer, 51:681.
Gabizon, G., Goren, D., Fuks, Z., Barenholz, Y., Dagan, A., and Meshorer, A., 1983, Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers, Cancer Res. 43:4730.
Gabizon, A., Dagan, A., Goren, D., Barenholz, Y., and Fuks, Z., 1982, Liposomes as in vivo carriers of adriamycin: Reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res. 42:4734.
Gabizon, A., Pappo, O., Goren, D., Chemla, M, Tzemach, D., and Horowitz, A.T., 1993b, Preclinical studies with doxorubicin encapsulated in polyethylene glycol-coated liposomes, J. Liposome Res. 3:517.
Gabizon, G., Chemla, M., Tzemach, D., Horowitz, A.T., and Goren, D., 1996, Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines, J. Drug Targeting, 3:391.
Gabizon, A., Goren, D., Horowitz, A.T., Tzemach, D., Lossos, A., and Siegal, T., 1997, Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals, Adv. Drug Deliv. Rev. 24:337.
Gabizon, A., Catane, R., Uziely, B., Kaufman, B., and Barenholz, Y., 1994, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes, Cancer Res. 54:987.
Goren, D., Horowitz, A.T., Zalipsky, S., Woodle, M.C., Yarden, Y., and Gabizon, A., 1996, Targeting of Stealth liposomes to erbB2 (Her/2) receptor: in vitro and in vivo studies. Br.J. Cancer, 74:1749.
Goren, D., Horowitz, A.T., Mandelbaum-Shavit, F., Tzemach, D., Zalipsky, S., and Gabizon, A., 1997, In vitro and in vivo studies of folate-targeted liposomes, Proc.Cont. Rel. Soc. 24:865.
Gregoriadis, G., ed., 1988, Liposomes as Drug Carriers: Recent Trends and Progress, Wiley, London.
Haran, G., Cohen, R., Bar., L.K. and Barenholz, Y., 1993, Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases, Biochim. Biophys. Acta,1151:201.
Harrison, D., Tomlinson, D., and Stewart, S., 1995, Liposomal entrapped doxorubicin:an active agent in aids-related Kaposi’s sarcoma, J. Clin. Oncol. 13:914.
Van Hoesel, Q.G., Steerenberg, P.A., Crommelin, D.J., Van Dijk, A., Van Oort, W., Klein, S., Douze, J.M., de Wildt, DJ., and Hillen, F.C., 1984, Reduced cardiotoxicity and nephrotoxicity with preservation of anti-tumor activity of doxorubicin entrapped in stable liposomes in the Lou/M Ws1 Rat, Cancer Res. 44:3698.
Lasic, D., and Martin, F., eds., 1995, Stealth Liposomes, Pharmacology and Toxicology series, CRC Press, Boca Raton, FL.
Lasic, D.D., Frederik, P.M., Stuart, M.C., Barenholz, Y., and McIntosh, T.J., 1992, Gelation of liposome interior a novel method for drug encapsulation, FEBS Lett. 312:255.
Lee, R.J., and Low, P.S., 1994, Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis, J. Biol. Chem. 269:3198.
Legha, S.S., Benjamin, R.S., Mackay, B., et al., 1982, Reduction of doxorubicin cardiotoxicity by prolonged continuous infusion, Ann Intern. Med 96:133.
Mayer, L.D., Tai, L.C., Bally, M.B., Mitilens, G.N., Ginsberg, R.S., and Cullis, P.R., 1990, Characterization of liposomal systems containing doxorubicin entrapped in response to pH gardients, Biochim.Biophys. Acta, 1025:143.
Mayhew, E., and Papahadjopoulos, D., 1983, Therapeutic application of liposomes. In: Liposomes, M.J. Ostro, ed., Marcel Dekker, New-York.
Minow, R.A., Benjamin, R.S., and Gottlieb, J.A., 1975, Adriamycin cardiomyopathy; an overview with determination of risk factors, Cancer Chemother. Rep. 6:195.
Muggia, F.M., Hainsworth, J.D., Jeffers, S., Miller, P., et al., and Liang.-Jung, L.J., 1997, Phase II study of liposomal doxorubicin in refractory ovarian carcinoma: anti-tumor activity and toxicity modification by liposomal encapsulation, J. Clin. Oncol. 15:987.
Olson, F., Mayhew, E., Maslow, D., Rustum, Y., and Szoka, F., 1982, Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes, Eur J. Cancer Clin. Oncol. 18:167.
Rahman, A., White, G., More, N., and Schein, P.S., 1985, Pharmacological, toxocological and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes, Cancer Res. 45:769.
Rahman, A., Fumagali, A., Barbieri, B., Schein, P.S., and Casazza, A.M., 1986, Anti-tumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes, Cancer Chemother. Pharmacol. 16:22.
Ranson, M.R., Carmichael, J., O’Byrne, K., Stewart, S., Smith, D., and Howell, A., 1997, Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J. Clin. Oncol. 15:3185.
Torchilin, V.P., 1995, Long circulating drug delivery systems, Adv. Drug Deliv. Rev. 16:125.
Unezaki, S., Maruyama, K., Ishido, O., Suginaka, A., Hosoda, J., and Iwatsuru, M., 1995, Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipathic poly(ethyleneglycol), Int. J. Pharm. 126:41.
Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Muggia, F.M., and Gabizon, A., 1995, Liposomal doxorubicin: anti-tumor activity and unique toxicities during two complementary phase I studies, J. Clin. Oncol. 13:1777.
Young, R.C., Ozols, R.F., and Myers, C.E., 1981, The anthracycline anti-neoplastic drugs, N. Engl. J.Med. 305:139.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Goren, D., Zalipsky, S., Horowitz, A.T., Gabizon, A. (1998). Stealth™ Liposomes as Carriers of Doxorubicin. In: Gregoriadis, G., McCormack, B. (eds) Targeting of Drugs 6. NATO ASI Series, vol 300. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0127-9_8
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0127-9_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0129-3
Online ISBN: 978-1-4899-0127-9
eBook Packages: Springer Book Archive